SAN DIEGO, September 17 — Puregraft, the global leader in the development and commercialization of autologous fat (adipose) grafting systems has received U.S. Patent Number 9,133,431 (the ‘431 patent) for its adipose filtration technology. The ‘431 patent covers methods and systems for optimizing fat grafts for current and future generations of the Puregraft technology. “The issuance of our foundational Puregraft patent by the United States Patent and Trademark Office solidifies the protectability of our novel Puregraft technology,” said Bradford A. Conlan, CEO of Puregraft LLC. “We also expect the Puregraft patent portfolio to strengthen outside the United States in the coming year.” In 15 minutes or less, the company’s FDA cleared and CE-Marked technology can provide a surgeon with purified adipose tissue for reinjection. The Puregraft technology is used today in hospitals and clinics around the world and provides physicians with confidence and convenience. Puregraft is positioned to continue its leadership in the rapidly expanding, fat grafting marketplace.
Learn more about Puregraft at www.puregraft.com and www.thefatexperts.com About Puregraft Puregraft is a private company owned by Bimini Technologies. The Bimini portfolio of products also includes Kerastem Technologies LLC (www.kerastem.com) a leading hair growth company currently engaged in a Phase II clinical trial in the United States. The Kerastem Hair Therapy is CE Mark approved outside the United States.